rapamycin inhibits cardiac hypertrophy by promoting autophagy via the mek/erk/beclin-1 pathway
Clicks: 294
ID: 206957
2016
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
294 views
64 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #164 of 461 articles by views in Journal of clinical and experimental dentistry
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 461 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Rapamycin, also known as sirolimus, is an antifungal agent and immunosuppressant drug used to prevent organ rejection in transplantation. However, little is known about the role of rapamycin in cardiac hypertrophy and the signaling pathways involved. Here, the effect of rapamycin was examined using phenylephrine (PE) induced cardiomyocyte hypertrophy in vitro and in a rat model of aortic banding (AB)-induced hypertrophy in vivo. Inhibition of MEK/ERK signaling reversed the effect of rapamycin on the upregulation of LC3-II, Beclin-1 and Noxa, and the downregulation of Mcl-1 and p62. Silencing of Noxa or Beclin-1 suppressed rapamycin-induced autophagy, and co-immunoprecipitation experiments showed that Noxa abolishes the inhibitory effect of Mcl-1 on Beclin-1, promoting autophagy. In vivo experiments showed that rapamycin decreased AB-induced cardiac hypertrophy in a MEK/ERK dependent manner. Taken together, our results indicate that rapamycin attenuates cardiac hypertrophy by promoting autophagy through a mechanism involving the modulation of Noxa and Beclin-1 expression by the MEK/ERK signaling pathway.
| Reference Key |
ewang2016frontiersrapamycin
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Changqian eWang;Gu eJun;Gu eJun;Wei eHu;Zhi-ping eSong;Yue-guang eChen;Da-dong eZhang |
| Journal | Journal of clinical and experimental dentistry |
| Year | 2016 |
| DOI |
10.3389/fphys.2016.00104
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.